Modulated gap junctional intercellular communication as a biomarker of PAH epigenetic toxicity: Structure-function relationship

Environmental Health Perspectives

Volumn 106, Issue SUPPL. 4, 1998, Pages 975-981

  Upham, Brad L ^a   Weis, Liliane M ^a   Trosko, James E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Epigenetic toxicity; Gap junctional intercellular communication; Polycyclic aromatic hydrocarbons; Tumor initiation; Tumor promotion

Indexed keywords

ANTHRACENE DERIVATIVE; CARCINOGEN; FLUORANTHENE; FLUORENE; MUTAGENIC AGENT; NAPHTHALENE; PHENANTHRENE; POLYCYCLIC AROMATIC HYDROCARBON;

ANIMAL CELL; CANCER; CARCINOGENESIS; CARCINOGENICITY; CELL COMMUNICATION; CHEMICAL MUTAGENESIS; CONFERENCE PAPER; EPITHELIUM CELL; GAP JUNCTION; GENETIC TOXICOLOGY; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TUMOR PROMOTION;

EID: 0031686703     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.98106s4975     Document Type: Conference Paper

References (65)

1. Trosko JE. Challenge to the simple paradigm that "carcinogens" are "mutagens" and to the in vitro assays used to test the paradigm. Mutat Res 373: 245-249 (1997).
2. Carson R. Silent Spring. Boston: Houghton MifBin, 1962.
3. Ames BN, Durston WE, Yamasaki E, Lee FD. Carcinogens are mutagens: A simple test system combining liver homogcnates for activation and bacteria for detection. Proc Natl Acad Sci USA 70: 2281-2285 (1973).
4. Trosko JE. Radiation-induced carcinoeenesis: paradigm considerations. In: Biological Effects or Low Level Exposures (Calabrese EJ, ed). Boca Raton, FL: Lewis Publishers, 1994;205-241.
5. f, Trosko JE, Chang CC. Nongenotoxic mechanisms in carcinogenesis: role of inhibited intercellular communication. In: Banbury Report 31: Carcinogen Risk Assessment: New Directions in the Qualitative and Quantitative Aspects (Hart RW, Hoerger FD, eds). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1988; 139-170.
6. Trosko JE, Chang CG, Madhukar BV. In vitro analysis of modulators of intercellular communication: implications for biologically based risk assessment models for chemical exposure. Toxicol in Vitro 4: 635-643 (1990).
7. Chronier L, Bastide B, Herve JC, Deleze J, Malassine A. Gap junctional communication during human trophoblast differentiation: influence of human chorionic gonadotropin. Endocrinology 135: 402-408 (1994).
8. De Mello WC. Gap junctional communication in excitable tissues: the heart as a paradigm. Prog Biophys Mol Biol 61: 1-35 (1994).
9. Christ J, Spray DG, El-Sabban M, Moore LK, Brink PR. Gap junctions in vascular tissues: evaluating the role of intercellular communication in the modulation of vasomotor tone. Circ Res 135: 251-264 (1996).
10. Munari-Silem Y, Rousset B. Gap junction-mediated cell-to-cell communication in endocrine glands: molecular and functional aspects: a review. Eur J Endocrinol 79: 631-646 (1996).
11. Stagg RB, Fletcher WH. The hormone-induced regulation of contact dependent cell-cell communication by phosphorylation. Endocrinol Rev 11: 302-325 (1990).
12. Trosko JE, Goodman JI. Intercellular communication may facilitate apoptosis: implications for tumor promotion. Mol Carcinog 11: 8-12 (1994).
13. Borek C, Sachs L. The difference in contact inhibition of cell replication between normal cells and cells transformed by different carcinogens. Proc Natl Acad Sci USA 56: 1705-1711 (1966).
14. Potter VR. Phenotypic diversity in experimental hepatomas: the concept of partially blocked ontogeny. Br J Cancer 38: 1-23 (1978).
15. Markert C. Neoplasia: a disease of differentiation. Cancer Res 28: 1908-1914(1968).
16. Trosko JE, Madhukar BV, Chang CC. Endogenous and exogenous modulation of gap junctional intercellular communication: toxicological and pharmacological implications. Life Sci 53: 1-19 (1993).
17. Yamasaki H, Naus CCC. Role of connexin genes in growth control. Carcinogenesis 17: 1199-1213 (1996).
18. Trosko JE, Chang CC, Madhukar BV, Dupont E. Oncogenes, tumor suppressor genes, and intercellular communication in the "Oncogeny as Partially Blocked Ontogeny" hypothesis. In: New frontiers in Cancer Causation (Iverson OH, ed). Washington: Taylor & Francis Publishers, 1993;181-197.
19. Goldberg GS, Martyn KD, Lau AF. A cpnnexin 43 antisense vector reduces the ability of normal cells to inhibit the foci formation of transformed cells. Mol Carcinog 11: 106-114 (1994).
20. Ruch RJ, Guan X, Sigler K. Inhibition of gap junctional intercellular communication and enhancement of growth in BALB/c 3T3 cells treated with connexin 43 antisense oligonucleotides. Mol Carcinog 14: 269-274 (1995).
21. Trosko JE, Chang CC, Madhukar BV, Dupont E. Intercellular communication: a paradigm for the interpretation of the initiation/promotion/progression model of carcinogenesis. In: Chemical Induction of Cancer: Modulation and Combination Effects (Arcos JC, Argus MF, Woo YT, eds). Boston: Birkhauser Publishers, 1996;205-225.
22. Boutwell RK. The function and mechanisms of promoters of carcinogenesis. CRC Crit Rev Toxicol 2: 419-443 (1974).
23. Pitot HC, Goldsworthy T, Moran S. The natural history of carcinogenesis: implications of experimental carcinogenesis in the genesis of human cancer. J Supramol Struct Cell Biochem 17: 133-146 (1981).
24. Potter VR. Use of two sequential applications of initiators in the production of hepatomas in the rat: An examination of the Solt-Farbcr Protocol. Cancer Res 44: 2733-2736 (1984).
25. Trosko JE, Chang CC, Medcalf A. Mechanisms of tumor promotion: potential role of intercellular communication. Cancer Invest 1: 511-526 (1983).
26. Ashby J, Tennant RW. Definitive relationships among chemical structure, carcinogcnicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat Res 257: 229-306 (1991).
27. Budunova IV, Williams GM. Cell culture assays for chemicals with tumor-promoting or tumor-inhibiting activity based on the modulation of intercellular communication. Oil Biol Toxicol 10: 71-116 (1994).
28. Rosenkranz M, Rosenkranz HS, Klopman G. Intercellular communication, tumor promotion and non-genotoxic carcinogenesis: relationships based upon structural considerations. Mutat Res 381: 171-188 (1997).
29. IARC. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol 32: Polynuclear Aromatic Compounds, Part 1: Chemical, Environmental and Experimental Data. Lyon: Tntemational Agency for Research on Cancer, 1983;95-447.
30. Pott P. Cancer scroti. In: The Chirurgical Works of Percivall Pott. Philadelphia: James Webster, 1819;291-295.
31. Hieger I, The spectra of cancer-producing tars and oils and of related substances. Biochem J 24: 505-511 (1930).
32. Kennaway KL, Hieger I. Carcinogenic substances and their fluorescence spectra. Br Med J 1: 1044-1046 (1930).
33. Dipple A, Moschel RC, Bigger CAH. Polynuclear aromatic carcinogens, In: Chemical Carcinogens. 2nd ed. Vol 1 (Searle CE, ed). ACS Monogr 182: 41-163 (1984).
34. Dipple A. Polynuclear aromatic carcinogens. In: Chemical Carcinogens (Searle CE, ed). ACS Monogr 173: 245-314 (1976).
35. Busby WF Jr, Goldman ME, Newberne PM, Wogan GN. Tumorigenicity of fluoranthene in a newborn mouse lung adenoma bioassay. Carcinogenesis 5: 1311-1316 (1984),
36. Wang J-S, Busby WF Jr. Induction of lung and liver tumors by fluoranthenc in a preweaning CD-1 mouse bioassay. Carcinogenesis 14: 1871-1874 (1993).
37. Stocker KJ, Howard WR, Statham J, Proudlock RJ. Assessment of the potential in vivo genotoxicity of fluoranthene. Mutagenesis 11: 493-496 (1996).
38. Upham BL, Masten SJ, Lockwood BR, Trosko JE. Nongenotoxic effects of polycyclic aromatic hydrocarbons and their ozonation by-products on the intercellular communication of rat liver epithelial cells. Fundam Appl Toxicol 23: 470-475 (1994).
39. Upham BL, Weis LM, Rummel AM, Masten SJ, Trosko JE. The effects of anthracene and methylated anthracenes on gap junctional intercellular communication in rat liver epithelial cells. Fundam Appl Toxicol 34: 260-264 (1996).
40. Rusch HP, Kline BE, Baumann CA. The nonadditive effect of ultraviolet light and other carcinogenic procedures. Cancer Res 2: 183-188 (1942).
41. Roc FJ. Effect of phenanthrene on tumor-initiation by 3,4-benzpyrene. Cancer 16: 503-506 (1963).
42. van Duuren BL, Goldschmidt BM. Cocarcinogenic and tumor-promoting agents in tobacco Carcinogenesis. J Nad Cancer Inst 56: 1237-1242 (1976).
43. Steiner PE, Falk HL. Summation and inhibition effects of weak and strong carcinogenic hydrocarbons: 1: 2-benzanthracene, chrysene, 1: 2: 5: 6-aibenzanthracene, and 20-methylcholanthrene. Cancer Res 11: 56-63 (1951).
44. Falk L, Kotin P, Thompson S. Inhibition of Carcinogenesis. Arch Environ Health 9: 169-179 (1964).
45. Hoffman D, Lavoie EJ, Hecht SS. Polynuclear aromatic hydrocarbons: effects of chemical srructurc on tumorigeniciry. In: Polynuclear Aromatic Hydrocarbons: Physical and Biological Chemistry (Cooke M, Dennis AJ, Fisher GL, eds). Columbus, OHrBartelle Press, 1982; 1-19.
46. Hoffmann D, Rathkamp G, Nesnow S, Wynder EL. Fluoranthenes: quantitative determination in cigarette smoke, formation bv pyrolysis, and tumor-initiating activity. J Natl Cancer Inst 49: 1165-1175 (1972).
47. Hecht SS, Loy M, Hoffmann D. On the structure and carcinogenicity of the methylchrysenes. In: Carcinogenesis. Vol 1: Polynuclear Aromatic Hydrocarbons: Chemistry, Metabolism and Carcinogenesis (Freudenthal RI, Jones PW, eds). New York: Raven Press, 1976;325-340.
48. Slaga T-J, Bowden GT, Scribner JD, Boutwell RK. Dose-response studies on the ability of 7,1 2-dimethylbenz[a]anthracene and benz[a]anthracene to initiate skin tumors. J Natl Cancer Inst 53: 1337-1340 (1974).
49. Slaga TJ, Iyer RP, Lyga W, Secrist A, Daub GH, Harvey RG. Comparison of the skin tumor-initiating activities of dihydrodiols, diolepoxides, and methylated derivatives of various polycyclic aromatic hydrocarbons. In: Polynuclear Aromatic Hydrocarbons: Chemistry and Biological Effects (Bjerscth A, Dennis AJ, eds). Columbus, OH: Batteile Press, 1980;753-769.
50. LaVoie FJ, Tulley-Freiler L, Bedenko V, Hoffmann D. Mutagenicity, tumor initiating activity, and metabolism of methylphenanthrencs. Cancer Res 41: 3441-3447 (1981).
51. LaVoie EJ, Coleman DT, Rice JE, Geddie NG, Hoffman D. Tumor-initiating activity, mutagcnicity, and metabolism of methylated anthracenes. Carcinogenesis 6(10): 1483-1488 (1985).
52. Kurihara T, Motohashi N, Pang G-L, Higano M, Kiguchi K, Molnar J. Correlations between ropological resonance energy of methyl-substituted benz[a]acridines, benz[a]phenothiazines and chrysenes, and their carcinogenic or antitumor activities. Anricancer Res 16: 2757-2766 (1996).
53. Flesher JW, Myers SR, Stansbury KH. The site of substitution of the methyl group in the bioalkylation of benz[a]pyrene. Carcinogenesis 11: 493-496 (1990).
54. Flesher JW, Myers SR. Bioalkylation of benz[a]anthracene as a biochemical probe for carcinogenic activity: lack of bioalkylation in a series of six noncarcinogenic polynuclear aromatic hydrocarbons. Drug Metab Dispos 18: 163-167 (1991).
55. Flesher JW, Myers SR. Rules of molecular geometry for predicting carcinogenic activity of unsubstituted polynuclear aromatic hydrocarbons. Teratog Carcinog Mutagen 11: 41-54 (1991).
56. Myers SR, Blake JW, Flesher JW. Bioalkylation and biooxidation of anthracene, in vitro add in vivo. Biochem Biophys Res Commun 151(3): 1441-1445 (1988).
57. Yang SK, Chu MW, Fu PP. Microsomal oxidations of methyl-substituted and unsubstituted aromatic hydrocarbons of monomethylbenz(a)anthracene. In: Polynuclear Aromatic-Hydrocarbons: Chemical Analysis and Biological Fate (Cooke M, Dennis AJ, eds). Columbus, OH: Battelle Press, 1980;253-264.
58. Watabe T, Ishizuka V, Isobe M, Ozawa N. A 7-hydroxymethyl sulfate ester as an active metabolite of 7,12-dimethyl-benz[a]anthracene. Science 215: 403-405 (1982).
59. Surh YJ, Liem A, Miller FC, Miller JA. Metabolic activation of the carcinogen 6-hydroxymethylbenzo[a]pyrene: formation of an electropnilic sulfuric acid ester and benzylic DNA adducts in rat liver in vivo and in reactions in vitro. Carcinogenesis 10: 1519-1528 (1989).
60. Surh YJ, Liem A, Miller EC, Miller, JA. 7-Sulfooxymethyl-12-methylbenz[a]anthracene Is an electrophilic mutagen, but does not appear to play a role in carcinogenesis by 7,12-dimetbylbenz[a]anthracene or 7-hydroxymethyl-12-methybenz[a]-anthracene. Carcinogenesis 12: 339-348 (1991).
61. Cheung YL, Gray TJB, loannides C. Mutagenicity of chrysene, its methyl and benzo derivatives, and their interactions with cytochromes P-450 and the Ah-receptor: relevance to their carcinogenic potency. Toxicology 81(1): 69-86 (1993).
62. 2+ and cell proliferation in primary human mammary epithelial cells. Carcinogenesis 18: 1177-1182 (1997).
63. Zhang Y, Ramos KS. The induction of proliferative vascular smooth muscle cell phenotypes by benzo[a]pyrene does not involve mutational activation of ras genes. Mutat Res 373: 285-292 (1997).
64. Upham BL, Jehng JY, Trosko, JK, Masten SJ. Determination of the efficacy of ozone treatment systems using a gap junction intercellular communication bioassay. Environ Sci Technol 29: 2923-2928 (1995).
65. Mackay D, Shu WY, Ma KC, eds. Polynuclear aromatic hydrocarbons, polychlorinatcd dioxins, dibenzofurans. In: Illustrated Handbook of Physical-Chemical Properties and Environmental Fate for Organic Chemicals. Vol VII. Chelsea, MI: Lewis Publishers, 1992;597.